"
Using a range of ProteinChip array chromatographic surfaces and wash
conditions, scientists can quickly identify those combinations that optimize
target protein purification conditions.com.

Safe Harbor Statement
Note Regarding Forward-Looking Statements: For purposes of the Private
Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements, and claims
the protection of the Safe Harbor for forward-looking statements contained in
the Act.

"The amino acid matching technology has been used internally to expedite
protein biomarker discovery, providing Nanogen the potential to identify novel
biomarkers of disease for future diagnostic product development. The essential task of
determining the amino acid sequence of an unknown protein depends on sorting
through a large amount of data generated by a mass spectrometer , which can be
time consuming and difficult. The success of the RNAi
assay is measured through gene expression (using tools such as microarrays
and quantitative PCR (qPCR) assays) as well as protein assays. With
the launch of this new offering, QIAGEN is once again demonstrating its
market and technology leadership by setting new standards in the converging
fields of siRNA-based gene silencing and gene expression analysis," said Jie
Kang QIAGEN's Vice President Research + Development .

Biology:instruments and supplies include all of the specialized apparatus, equipment, services and other 'stuff' that scientific researchers, teachers, and engineers working in the field of Biology need in the course of their work .

cdna shandon

In addition, variables such as noise
filtration, offsets in samples and multiple sample preparation methods can
result in unacceptable readings from several samples.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop diagnostic tests for
variety of diseases. The offering
addresses a critical need in research and drug development.

The new offering developed by QIAGEN provides a very broad range of
optimized and validated RNAi-based gene silencing solutions and, in addition,
also links such RNAi solutions with the corresponding gene expression assay
used in the subsequent qPCR-based knockdown validation.
Both are highly potent and specific siRNA products which deliver
guaranteed knockdown. Securities Act of 1933, as amended, and Section 21E of the U.

bioprocessing transgenics

Rich, President and CEO of Ciphergen.

cdna oligonucleotides

ProteinChip Systems enable protein
discovery, characterization, identification and assay development to provide
researchers with predictive, multi-marker assay capabilities and a better
understanding of biological function at the protein level. Alternatively a SBU can be used as a label to detect a specific
nucleic acid .

Gene Silencing, or RNA interference (RNAi) uses target-specific sequences
of short interfering RNA molecules (siRNA molecules) to knock-down, or
"silence" targeted genes to infer their function. The matching ready-to-use and validated SYBR(R)
Green-based qRT-PCR assay portfolio is supplemented by QIAGEN's QuantiTect(R)
Primer Assays for real-time RT-PCR providing specificity and sensitivity
comparable to sequence-specific probe-based assays. In addition, all
offerings are linked to corresponding pre-analytical solutions from QIAGEN
and therefore allow a complete and seamlessly integrated workflow. In
addition, QIAGEN is positioning its products for sale into developing
commercial markets, including DNA sequencing and genomics, nucleic acid-based
molecular diagnostics , and genetic vaccination and gene therapy. To the extent that any of the
statements contained herein relating to QIAGEN's products, markets, strategy
or operating results are forward-looking, such statements are based on
current expectations that involve a number of uncertainties and risks.

transgenics tbe

This method greatly aids in providing rapid protein
sequencing as well as purification for protein-protein interaction studies,
crystallography or activity assays. patents now includes intellectual
property related to novel biomarker discovery technology and methods of
isolating nucleic acids on a microarray. QIAGEN believes
that this new offering represents a substantial improvement over current
offerings and that it provides access to a new dimension of value for
customers in the rapidly growing field of RNAi.

expirations transgenics

Complements Existing Patents Covering Ciphergen's Pattern Track(TM) Biomarker
Discovery to Assay Process including Protein Identification

FREMONT, Calif. The SBU can act similarly to the commonly-used
biotin/strepavidin binding pair but many different SBU pairs can be
synthesized .GeneGlobe. GeneGlobe
will allow QIAGEN's customers to find information about, to search for, and
to order high-quality products for human, mouse, and rat genes. Securities and Exchange
Commission (SEC).

bioanalytik cdna

Additional information
about Ciphergen can be found at http://www. 6,891,154, "Amino Acid Sequence Pattern Matching" and No.
"The technology that these patents cover can improve our ability to find
appropriate biomarkers and can improve the use of multiplexing in diagnostics,
helping us to bring valuable diagnostic solutions to the market," said Howard
C. In addition,
our SBU technology promotes specificity and flexibility in the use of our
microarrays.
In addition QIAGEN has launched GeneGlobe (http://www.

Pick an appropriate subcategory and then submit your English Language site there.

immunoassays bioanalytik

Ciphergen Announces Issuance of Patent for SELDI-TOF-MS Assisted Protein Purification

The methods involve using
ProteinChip(R) chromatographic arrays integrated with SELDI-TOF-MS detection
to rapidly identify "on-chip" conditions for purifying a protein for
applications including protein identification.

About Ciphergen
Ciphergen's Biosystems Division develops, manufactures and markets a
family of ProteinChip(R) Systems and services for clinical, research, and
process proteomics applications."
Nanogen's growing portfolio of 128 U.

About Nanogen, Inc. For additional information please visit
Nanogen's website at http://www.

cytogenetics thermocyclers

"Our
Biomarker Discovery Center(R) scientists as well as leading researchers in our
customer base have successfully used this process to purify and identify
protein biomarkers discovered and validated through our Pattern Track
process. Ciphergen's
Diagnostics Division is dedicated to the discovery of protein biomarkers and
panels of biomarkers and their development into protein molecular diagnostic
tests that improve patient care; and to providing collaborative R+D services
through its Biomarker Discovery Center(R) laboratories for biomarker discovery
for new diagnostic tests as well as pharmacoproteomic services for improved
drug toxicology, efficacy and theranostic assays. Nanogen also offers a broad portfolio of patented
nucleic acids chemistries and molecular tools that accelerate genomic analysis
and are compatible with many systems.
(NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), the world 's leading provider
of innovative enabling technologies and products for the separation,
purification and handling of nucleic acids and proteins today announced the
launch of what it believes is the world's first and largest product portfolio
for integrated genome-wide RNAi and SYBR(R) Green-based RT-PCR. Today, QIAGEN
provides a vast range of gene-specific products covering the whole RNAi
workflow from transfection to the subsequent qPCR analysis.
Securities Exchange Act of 1934, as amended.

04/21/00

thermocyclers phosphates

Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. RNAi and gene
expression assays are therefore often used in concert and their
synchronization is a key requirement and challenge for successful research.

thermocyclers chromatographic

The SBUs only bind to a very specific complement SBU, which may be on a
microarray chip. In a multiplex amplification, unique primers can be paired with
unique SBUs so that upon detection on a microarray, the amplified products
array themselves automatically to bind with a complementary SBU attached to
the array.

bioprocessing oligonucleotides

(Nasdaq: CIPH) announced today that the United States Patent and
Trademark Office has issued Ciphergen U.

Nanogen Issued Patents for Biomarker Discovery and Nucleic Acid Manipulation Technologies

This sequence pattern
matching software is designed to provide a superior method for analyzing a
large amount of data to identify unique amino acid sequences quickly, which is
key to proteomic biomarker discovery. Nanogen's ten years of pioneering research involving
nanotechnology may also have future applications in medical diagnostics,
biowarfare and other industries. Validated Solutions Allow Integrated RNAi and Gene Expression Analysis
for Human, Mouse and Rat Genomes

VENLO, The Netherlands, QIAGEN N.com), an
easy-to-use, comprehensive Web portal for gene specific products. RNAi represents a fundamental and
revolutionary technology for functional genomics and systems biology.
QIAGEN has developed a comprehensive portfolio of more than 320 proprietary ,
consumable products for nucleic acid and protein separation, purification and
handling, nucleic acid amplification, as well as automated instrumentation,
synthetic nucleic acid products and related services.
Certain of the statements contained in this news release may be
considered forward -looking statements within the meaning of Section 27A of
the U. Such
uncertainties and risks include , but are not limited to, risks associated
with management of growth and international operations (including the effects
of currency fluctuations and risks of dependency on logistics), variability
of operating results, the commercial development of the DNA sequencing,
genomics and proteomics markets, nucleic acid-based molecular diagnostics
market, and genetic vaccination and gene therapy markets, competition, rapid
or unexpected changes in technologies, fluctuations in demand for QIAGEN 's,
products (including seasonal fluctuations), difficulties in successfully
adapting QIAGEN's products to integrated solutions and producing such
products, the ability of QIAGEN to identify and develop new products and to
differentiate its products from competitors, market acceptance of QIAGEN 's
new products and the integration of acquisitions of technologies and
businesses.

Don 't think that a long flowery non-professional discription will get your site listed any faster, it won 't.

oligonucleotides tbe

The '822 patent adds to a family of technologies that allows
for novel methods of active construction of arrays of immobilized nucleic
acids utilizing prefabricated arrays of SBUs.
The siRNA assay portfolio comprises two types of siRNA products from
QIAGEN, the HP GenomeWide and the HP Validated siRNAs. The launch of this new
offering allows customers to purchase proven siRNAs and RT-PCR assays for
every gene of the human, mouse, and rat genomes.
"This exciting product launch positions QIAGEN as the leading provider
for standardized solutions in RNAi.

incyte cryobiology

About QIAGEN:
QIAGEN N.

incyte cycler

Patent 6,881,586, directed to
methods of rapidly purifying proteins.

NOTE: Ciphergen , ProteinChip and Biomarker Discovery Center are
registered trademarks of Ciphergen Biosystems, Inc .
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.

glycine thermocyclers

Scientists can then translate these
on-chip conditions into a column chromatography protocol for purifying the
protein at lab scale.S. Birndorf , Nanogen's chairman of the board and chief executive officer. These forward-looking statements speak only as of the
date hereof. For further information, refer to the discussion in reports that
QIAGEN has filed with, or furnished to, the U.

Please remember, multiple submissions of the same URL to the same category will not get your site listed any faster.

sirna immunoassays

Patent and Trademark Office, including U.V.

Industrial scale devices and supplies will not be listed in this category.

antisense cycler

Patent
No.
The '822 patent relates to methods using novel synthetic binding units
(SBUs) with very high specificity and sensitivity, linked to nucleic acids as
primers in a PCR or other nucleic acid amplification and detection reaction. Nanogen disclaims any intent or obligation to update these
forward-looking statements.

QIAGEN Launches the First Validated Portfolio Linking Genome-Wide RNAi and qPCR-Based Gene Expression Assays

expirations perkinelmer

S.S. QIAGEN's products are
sold in more than 42 countries throughout the world to academic research
markets and to leading pharmaceutical and biotechnology companies.

cryobiology cycler

Examples of such forward-looking statements include statements
regarding the use of ProteinChip arrays to rapidly purify proteins for protein
identification, interaction studies, crystallography or activity assays as
well as statements regarding the diagnostic tests that Ciphergen Diagnostics
is developing . Investors should consult Ciphergen's filings with
the Securities and Exchange Commission, including its Form 10-Q dated May 10,
2005, for further information regarding these and other risks of the Company's
business. SAN DIEGO, Nanogen, Inc. Further information on QIAGEN
can be found at http://www.S.

antisense bioanalytik

"Protein purification is a major bottleneck today in protein
identification ," said William E., a Netherlands holding company with subsidiaries in Germany,
the United States , Japan, the United Kingdom, Switzerland, France, Italy,
Australia, Norway, Austria, Canada, and the Netherlands believes it is the
world's leading provider of innovative enabling technologies and products for
the separation, purification and handling of nucleic acids and proteins.qiagen.com.

scie chromatographic

ciphergen .nanogen. QIAGEN
employs approximately 1,400 people worldwide.

The preferred structure is to have the title show the company name and have the description demonstrate why your site belongs in a particular subcategory of Instruments and Supplies (meaning, write a couple of sentences describing the appropriate product line or lines).

The first word of your title should be your company name, the first word of the description should be the main service, device or product you list on your site.

oligonucleotides cycler

(Nasdaq: NGEN),
developer of advanced diagnostic products, announced today it was issued two
patents from the U. The software was developed by SynX
Pharma, a Nanogen subsidiary. The features of this
validated offering create a new dimension in utility and ease of use by
eliminating the need for laborious and time-consuming assay development which
consumes costly probe-based qRT-PCR reagents as well as eliminating the need
to repeatedly design, synthesize, and test siRNA and primers . These siRNA products
were designed using the innovative HiPerformance siRNA Design Algorithm,
licensed from Novartis Pharmaceuticals, a unique combination of the design
algorithm with QIAGEN's proprietary sensitive homology search.

Your product, device, or service must be related to biology laboratory work or biology education in some way, to be listed in Science/Instruments and Supplies.

incyte perkinelmer

S."
The '154 patent relates to software designed for amino acid sequencing
pattern matching and determining the number of possible sequences consistent
with the molecular weight of the amino acid.

All this means is I have to waste my time editing your discription to fit ODP criteria.

If I cannot find your product, device, or service in a biology research lab, biology department research lab, university or high school biology educational lab, you will not find your site listed here.

cyclers expirations

, Ciphergen Biosystems ,
Inc. Actual results may differ materially from those projected in
such forward-looking statements due to various factors, including ProteinChip
technology's ability to consistently and rapidly purify proteins, ProteinChip
technology's ability to successfully discover, validate and assay biomarkers
and patterns of biomarkers that are highly predictive and therefore meet with
customer acceptance as diagnostics, and our ability to protect and promote our
proprietary technologies. 6,893,822,
"Enzymatic modification of a nucleic acid-synthetic binding unit conjugate. The SynX subsidiary offers a line of
point-of-care diagnostic tests and is building expertise in cardiac related
health conditions .com.V.S.

If you believe there are two or three appropriate subcategories, then submit your site to all of them, but do not submit to every subcategory in Instruments and Supplies.